Tucatinib

Contraindicated

Tucatinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Tucatinib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Tucatinib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Tucatinib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Tucatinib Ivabradine Corlanor Increased ivabradine exposure and an increased risk of ivabradine-related adverse effects [like bradycardia and conduction disturb... Details Tucatinib Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Tucatinib Lurasidone Latuda Increased lurasidone exposure Details Tucatinib Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details

Major

Tucatinib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Tucatinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Tucatinib Clindamycin ANTIROBE Explained Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Tucatinib Relugolix Orgovyx Explained Increased relugolix exposure Details Tucatinib Abemaciclib Verzenio Explained Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Acalabrutinib Calquence Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Tucatinib Aripiprazole Injection Abilify Increased ARIPiprazole exposure Details Tucatinib Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Tucatinib Atogepant Qulipta Increased atogepant exposure Details Tucatinib Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Tucatinib Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Tucatinib Abiraterone Abirtega Increased tucatinib exposure and risk of toxicity Details Tucatinib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Tucatinib Axitinib Inlyta Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Tucatinib Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Tucatinib Bedaquiline Sirturo Increased bedaquiline exposure Details Tucatinib Bosutinib Bosulif Increased bosutinib exposure Details Tucatinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Tucatinib Brigatinib Alunbrig Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Budesonide Entocort Increased budesonide exposure Details Tucatinib Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Tucatinib Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Tucatinib Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Tucatinib Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Tucatinib Clindamycin Injection ANTIROBE Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Clindamycin Topical C/T/S® Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Clindamycin Vaginal Cleocin Increased exposure to CYP3A substrate and risk of toxicity Details Tucatinib Clopidogrel Plavix Increased tucatinib exposure and risk of toxicity Details Tucatinib Cobimetinib Cotellic Increased exposure to CYP3A substrate and risk of toxicity Details